Health Condition 1: K729- Hepatic failure, unspecified
Conditions
Interventions
Intervention1: Norfloxacin: Norfloxacin 400mg once daily for 30 days + SMT (Standard medical therapy).
Control Intervention1: Placebo: Matched Placebo once daily for 30 days + SMT(Standard medical the
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: ACLF patients aged between 18-75 years, either admitted or attending the out-patient department will be recruited for the study.
Exclusion criteria
Exclusion criteria: 1. Patients with sepsis â?? fever, positive blood, and urine cultures, procalcitonin >2, Allergy to fluoroquinolones. 2.Patients in the intensive care unit 3.Renal failure (S. Creatinine >2.5mg%) 4.Pregnancy 5.Patients with a history of Spontaneous bacterial peritonitis 6.Patients with shock requiring vasopressor support 7.Patients with malignancy 8.Recent Gastrointestinal bleeding ( 9.Patients with a history of Hepatic encephalopathy and /or on Rifaximin therapy 10.Patients who received fluoroquinolones in last one month 11.Patients on intravenous antibiotics 12.Refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of sepsisTimepoint: at day 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of norfloxacin on Endotoxin levelsTimepoint: on day 7, 30;To study the safety and tolerability of the Norfloxacin.Timepoint: at day 30;Transplant-free survivalTimepoint: at day 30, 90. | — |
Countries
India
Contacts
Public ContactAnand V Kulkarni
AIG Hospital
Outcome results
None listed